title: Influence of celecoxib on the vasodilating properties of human mesenteric arteries constricted with endothelin-1.
abstract: The mitogenic and vasoconstrictive properties of the vascular system are attributed to endothelin-1 (ET-1). ET-1 serum concentration increases in a number of pathological conditions, particularly in those associated with blood vessel constriction. ET-1 is also associated with the underlying pathomechanisms of primary pulmonary hypertension, arterial hypertension and eclampsia. The aim of this study was to compare the vasodilating properties of selected phosphodiesterase (PDE) inhibitors and celecoxib in human mesenteric arteries constricted with ET-1, and investigate the role of the endothelium in relaxation. Perfused human mesenteric arteries were collected and stored under the same conditions as organs for transplantation. The mesenteric arteries (with and without the endothelium) were constricted by the addition of ET-1 and treated with one of the following: sildenafil (PDE5 inhibitor), zaprinast (PDE5 and 6 inhibitor), rolipram (PDE4 inhibitor) and celecoxib [cyclooxygenase-2 (COX-2) inhibitor]. Based on the observed changes of the perfusion pressure, concentration response curves (CRCs) were prepared for the respective inhibitors and the EC50(concentration causing an effect equal to half of the maximum effect), pD2(negative common logarithm of EC50) and relative potency (RP) were calculated. The results suggested that all the inhibitors triggered a concentration-dependent decrease in the perfusion pressure in isolated human superior mesenteric arteries with endothelium constricted by the addition of ET-1. In the arteries without endothelium, CRCs for celecoxib and rolipram were shifted to the right without a significant decrease in the maximum dilating effect. Moreover, CRCs for sildenafil and zaprinast were shifted to the right with a simultaneous significant decrease in the maximum dilating effect and with an increased inclination angle in reference to the concentration axis. In the presence of the endothelium, all of the evaluated PDE inhibitors, as well as celecoxib, reduced the reactivity of the mesenteric arteries caused by ET-1. Sildenafil indicated the lowest efficacy in the presence of the endothelium, but showed a higher potency compared to that of the other compounds. Removing the endothelium significantly reduced the vasodilating efficacy of PDE5 and 6 inhibitors and a statistically significant influence on the vasodilating efficacy of PDE4 inhibitor and celecoxib was observed. The high vasorelaxing efficacy of celecoxib at the background of the PDE inhibitors was observed, not only in the presence, but also in the absence of the endothelium and may be evidence for the relaxation induced by this COX-2 inhibitor in the cAMP- and cGMP-dependent pathways.
authors.affiliation: Department of Pharmacology and Therapeutics, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz 85-094, Poland.
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Grześk
authors.affiliation: Department of Pharmacology and Therapeutics, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz 85-094, Poland.
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Szadujkis-Szadurska
authors.affiliation: Department of Pharmacology and Therapeutics, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz 85-094, Poland.
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Matusiak
authors.affiliation: Department of Pharmacology and Therapeutics, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz 85-094, Poland.
authors.forename: Bartosz
authors.initials: B
authors.lastname: Malinowski
authors.affiliation: Department of Pharmacology and Therapeutics, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz 85-094, Poland.
authors.forename: Marta
authors.initials: M
authors.lastname: Gajdus
authors.affiliation: Department of Pharmacology and Therapeutics, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz 85-094, Poland.
authors.forename: Michał
authors.initials: M
authors.lastname: Wiciński
authors.affiliation: Department of Pharmacology and Therapeutics, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz 85-094, Poland.
authors.forename: Leszek
authors.initials: L
authors.lastname: Szadujkis-Szadurski
keywords: celecoxib; constriction; endothelin-1; endothelium; phosphodiesterase inhibitors
references.citation: Circ Res. 2007 Jun 8;100(11):1569-78
references.pmid: 17556670
references.citation: J Clin Pharmacol. 2007 Jan;47(1):70-7
references.pmid: 17192504
references.citation: Pharmacol Rev. 2006 Sep;58(3):488-520
references.pmid: 16968949
references.citation: Thromb Res. 2012 Jul;130(1):65-9
references.pmid: 22265722
references.citation: Physiol Rev. 2003 Oct;83(4):1325-58
references.pmid: 14506307
references.citation: Mol Interv. 2006 Aug;6(4):199-207
references.pmid: 16960142
references.citation: Eur J Clin Pharmacol. 2010 Jun;66(6):619-25
references.pmid: 20157701
references.citation: Am J Physiol Heart Circ Physiol. 2006 Jul;291(1):H260-8
references.pmid: 16489110
references.citation: Rev Esp Cardiol. 2009 Aug;62(8):851-7
references.pmid: 19706240
references.citation: Arterioscler Thromb Vasc Biol. 2007 Feb;27(2):266-74
references.pmid: 17138941
references.citation: Circ Res. 2003 Aug 22;93(4):280-91
references.pmid: 12933699
references.citation: Lancet. 2004 May 29;363(9423):1751-6
references.pmid: 15172772
references.citation: Br J Pharmacol. 2008 Aug;154(8):1631-9
references.pmid: 18516068
references.citation: Circulation. 2003 Jan 28;107(3):405-9
references.pmid: 12551863
references.citation: Am J Physiol. 1994 Jul;267(1 Pt 2):H326-32
references.pmid: 8048598
references.citation: N Engl J Med. 2004 Oct 21;351(17):1709-11
references.pmid: 15470192
references.citation: Transplant Proc. 2007 Jun;39(5):1350-3
references.pmid: 17580137
references.citation: Cancer Prev Res (Phila). 2010 May;3(5):588-96
references.pmid: 20403998
references.citation: N Engl J Med. 2005 Mar 17;352(11):1081-91
references.pmid: 15713945
references.citation: Drugs Aging. 2004;21(7):479-84
references.pmid: 15132714
references.citation: Am J Physiol Heart Circ Physiol. 2009 Nov;297(5):H1882-8
references.pmid: 19783781
references.citation: Cardiovasc Res. 2008 Jul 1;79(1):161-8
references.pmid: 18456673
references.citation: Am J Med. 2011 Jul;124(7):614-20
references.pmid: 21596367
references.citation: Hypertension. 2003 Sep;42(3):310-5
references.pmid: 12874094
references.citation: J Clin Invest. 2006 Jan;116(1):4-15
references.pmid: 16395396
references.citation: Cardiovasc Res. 2007 Jul 15;75(2):390-7
references.pmid: 17383621
references.citation: Science. 2002 Apr 19;296(5567):539-41
references.pmid: 11964481
references.citation: Cell Metab. 2005 Sep;2(3):201-7
references.pmid: 16154102
references.citation: Arch Intern Med. 2005 Mar 14;165(5):490-6
references.pmid: 15710786
references.citation: N Engl J Med. 2005 Mar 17;352(11):1071-80
references.pmid: 15713944
references.citation: Circ Res. 2006 Feb 3;98(2):e11-8
references.pmid: 16397147
references.citation: Am J Physiol Renal Physiol. 2007 May;292(5):F1443-51
references.pmid: 17229677
references.citation: Endocrinology. 2007 Sep;148(9):4162-9
references.pmid: 17510245
references.citation: J Rheumatol. 2004 Jun;31(6):1143-51
references.pmid: 15170928
references.citation: Circulation. 2003 Nov 4;108(18):2172-83
references.pmid: 14597579
references.citation: Am J Physiol Cell Physiol. 2001 Dec;281(6):C1743-56
references.pmid: 11698232
references.citation: J Neurosci Res. 2011 Mar;89(3):320-8
references.pmid: 21259319
references.citation: N Engl J Med. 2005 Mar 17;352(11):1092-102
references.pmid: 15713943